ABSTRACT
PURPOSE: CT-guided percutaneous core biopsy of the lung is usually performed under local anesthesia, but can also be conducted under additional systemic opioid medication. The purpose of this retrospective study was to assess the effect of intravenous piritramide application on the pneumothorax rate and to identify risk factors for post-biopsy pneumothorax. MATERIALS AND METHODS: One hundred and seventy-one core biopsies of the lung were included in this retrospective single center study. The incidence of pneumothorax and chest tube placement was evaluated. Patient-, procedure- and target-related variables were analyzed by univariate and multivariable logistic regression analysis. RESULTS: The overall incidence of pneumothorax was 39.2% (67/171). The pneumothorax rate was 31.5% (29/92) in patients who received intravenous piritramide and 48.1% (38/79) in patients who did not receive piritramide. In multivariable logistic regression analysis periinterventional piritramide application proved to be the only independent factor to reduce the risk of pneumothorax (odds ratio 0.46, 95%-confidence interval 0.24, 0.88; p = 0.018). Two or more pleura passages (odds ratio 3.38, 95%-confidence interval: 1.15, 9.87; p = 0.026) and prone position of the patient (odds ratio 2.27, 95%-confidence interval: 1.04, 4.94; p = 0.039) were independent risk factors for a higher pneumothorax rate. CONCLUSION: Procedural opioid medication with piritramide proved to be a previously undisclosed factor decreasing the risk of pneumothorax associated with CT-guided percutaneous core biopsy of the lung. LEVEL OF EVIDENCE 4: small study cohort.
Subject(s)
Analgesics, Opioid , Image-Guided Biopsy , Lung , Pirinitramide , Pneumothorax , Radiography, Interventional , Tomography, X-Ray Computed , Humans , Pneumothorax/prevention & control , Pneumothorax/etiology , Female , Male , Retrospective Studies , Tomography, X-Ray Computed/methods , Middle Aged , Analgesics, Opioid/administration & dosage , Radiography, Interventional/methods , Aged , Image-Guided Biopsy/adverse effects , Image-Guided Biopsy/methods , Risk Factors , Lung/diagnostic imaging , Lung/pathology , Pirinitramide/administration & dosage , Pirinitramide/therapeutic use , Adult , IncidenceABSTRACT
There is a rising number in complications associated with more cardiac electrical devices implanted (CIED). Infection and lead dysfunction are reasons to perform transvenous lead extraction. An ideal anaesthetic approach has not been described yet. Most centres use general anaesthesia, but there is a lack in studies looking into deep sedation (DS) as an anaesthetic approach. We report our retrospective experience for a large number of procedures performed with deep sedation as a primary approach. Extraction procedures performed between 2011 and 2018 in our electrophysiology laboratory have been included retrospectively. We began by applying a bolus injection of piritramide followed by midazolam as primary medication and would add etomidate if necessary. For extraction of leads a stepwise approach with careful traction, locking stylets, dilator sheaths, mechanical rotating sheaths and if needed snares and baskets has been used. A total of 780 leads in 463 patients (age 69.9 ± 12.3, 31.3% female) were extracted. Deep sedation was successful in 97.8% of patients. Piritramide was used as the main analgesic medication (98.5%) and midazolam as the main sedative (94.2%). Additional etomidate was administered in 15.1% of cases. In 2.2% of patients a conversion to general anaesthesia was required as adequate level of DS was not achieved before starting the procedure. Sedation related complications occurred in 1.1% (n = 5) of patients without sequalae. Deep sedation with piritramide, midazolam and if needed additional etomidate is a safe and feasible strategy for transvenous lead extraction.
Subject(s)
Anesthetics , Deep Sedation , Defibrillators, Implantable , Etomidate , Pacemaker, Artificial , Humans , Female , Male , Midazolam/adverse effects , Retrospective Studies , Pirinitramide , Deep Sedation/adverse effects , Deep Sedation/methods , Device Removal/adverse effects , Device Removal/methods , Treatment Outcome , Pacemaker, Artificial/adverse effectsABSTRACT
Se presenta la experiencia clínica y terapéutica en setenta y siete (77) casos de linfadenopatía toxoplasmósica. Se demuestra la independencia entre el tratamiento y la evolución clínica y serológica en pacientes con la forma no febril de la toxoplasmosis ganglionar. Se concluye que el tratamiento específico sólo está indicado en los pacientes febriles